Denali Therapeutics Inc. (DNLI)
- Previous Close
15.99 - Open
15.69 - Bid 11.09 x 200
- Ask 13.97 x 400
- Day's Range
13.90 - 16.17 - 52 Week Range
10.57 - 33.33 - Volume
2,084,189 - Avg. Volume
1,394,361 - Market Cap (intraday)
2.322B - Beta (5Y Monthly) 1.49
- PE Ratio (TTM)
-- - EPS (TTM)
-2.57 - Earnings Date Jul 30, 2025 - Aug 4, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
36.44
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for amyotrophic lateral sclerosis; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
www.denalitherapeutics.comRecent News: DNLI
View More
Performance Overview: DNLI
Trailing total returns as of 5/6/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DNLI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DNLI
View MoreValuation Measures
Market Cap
2.03B
Enterprise Value
1.25B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.65
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-24.82%
Return on Equity (ttm)
-37.40%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-422.77M
Diluted EPS (ttm)
-2.57
Balance Sheet and Cash Flow
Total Cash (mrq)
832.33M
Total Debt/Equity (mrq)
4.42%
Levered Free Cash Flow (ttm)
-208.83M